February 9, 2024

A recent review explores mast cell silencing as a novel therapeutic approach for urticaria. New experimental mast cell silencers like Siglec-targeted monoclonal antibodies (e.g., lirentelimab, AK006) might revolutionize the management of mast cell-dependent diseases, including urticaria. Urticaria is a complex, chronic skin health issue. Its underlying mechanism is not fully understood, posing treatment challenges. Urticaria...